Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
ADiTx Therapeutics, Inc is a biotechnology business based in the US. ADiTx Therapeutics shares (ADTX) are listed on the NASDAQ and all prices are listed in US Dollars. ADiTx Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of USD$40.7 million.
|52-week range||USD$1.655 - USD$7.08|
|50-day moving average||USD$2.9906|
|200-day moving average||USD$2.5812|
|Wall St. target price||USD$14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.6019|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-83.89%|
|Return on equity TTM||-224.27%|
|Market capitalisation||USD$40.7 million|
TTM: trailing 12 months
There are currently 350,055 ADiTx Therapeutics shares held short by investors – that's known as ADiTx Therapeutics's "short interest". This figure is 16.8% down from 420,805 last month.
There are a few different ways that this level of interest in shorting ADiTx Therapeutics shares can be evaluated.
ADiTx Therapeutics's "short interest ratio" (SIR) is the quantity of ADiTx Therapeutics shares currently shorted divided by the average quantity of ADiTx Therapeutics shares traded daily (recently around 372398.93617021). ADiTx Therapeutics's SIR currently stands at 0.94. In other words for every 100,000 ADiTx Therapeutics shares traded daily on the market, roughly 940 shares are currently held short.
However ADiTx Therapeutics's short interest can also be evaluated against the total number of ADiTx Therapeutics shares, or, against the total number of tradable ADiTx Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ADiTx Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 ADiTx Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0282% of the tradable shares (for every 100,000 tradable ADiTx Therapeutics shares, roughly 28 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ADiTx Therapeutics.
Find out more about how you can short ADiTx Therapeutics stock.
We're not expecting ADiTx Therapeutics to pay a dividend over the next 12 months.
ADiTx Therapeutics, Inc. , a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. ADiTx Therapeutics has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.